Document is current
Any future updates will be listed below
-
Authors
Freeman, Jincong Q.
Schechter, Kent
Nguyen, Long C.
Omoleye, Olasubomi J.
Hara, Jared H.
-
Funding
Funding for this research was provided by:
Susan G. Komen (TREND21675016)
Susan G. Komen (CTA241185923)
National Institute on Aging (T32AG000243)
University of Chicago Quad Undergraduate Research Grant
University of Chicago Comprehensive Cancer Center Sigal Fellowship in Immuno-Oncology
- License Information
-
More Information
Article History
Received: 11 July 2025
Accepted: 13 October 2025
First Online: 21 November 2025
Declarations
:
: K.S. is founder, CEO, and a shareholder of Tilden Therapeutics Inc., a biotechnology startup aimed at advancing therapies for metastatic cancer patients.
: Given the use of de-identified data from the National Cancer Database, this study was deemed exempt from Institutional Review Board review.
